Stoke’s Phase 3 Trial of STK-001 for Dravet Planned for Next Year
STK-001, Stoke Therapeutics' treatment for Dravet syndrome, shows promise in reducing seizures in children and adolescents, with Phase 1/2a trials indicating safety and efficacy. Interim results suggest a shift towards syndrome management, with further data expected to inform Phase 3 trials. STK-001 aims to restore NaV1.1 levels, potentially improving quality of life.
Related Clinical Trials
Reference News
Stoke’s Phase 3 Trial of STK-001 for Dravet Planned for Next Year
STK-001, Stoke Therapeutics' treatment for Dravet syndrome, shows promise in reducing seizures in children and adolescents, with Phase 1/2a trials indicating safety and efficacy. Interim results suggest a shift towards syndrome management, with further data expected to inform Phase 3 trials. STK-001 aims to restore NaV1.1 levels, potentially improving quality of life.